Oncolytics Biotech Inc. (ONC.TO)
CAD 1.1
(-2.65%)
CAD 1.1
(-2.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -31.11 Million CAD | -175.49% |
| 2022 | -11.29 Million CAD | 72.19% |
| 2021 | -40.6 Million CAD | -31.77% |
| 2020 | -30.81 Million CAD | -125.91% |
| 2019 | -13.64 Million CAD | 0.42% |
| 2018 | -13.69 Million CAD | -15.75% |
| 2017 | -11.83 Million CAD | 1.65% |
| 2016 | -12.03 Million CAD | 49.89% |
| 2015 | -24.01 Million CAD | -69.69% |
| 2014 | -14.15 Million CAD | 43.88% |
| 2013 | -25.22 Million CAD | -30.52% |
| 2012 | -19.32 Million CAD | 41.3% |
| 2011 | -32.91 Million CAD | 16.23% |
| 2010 | -39.29 Million CAD | -15.66% |
| 2009 | -33.97 Million CAD | -357.31% |
| 2008 | -7.42 Million CAD | -10.64% |
| 2007 | -6.71 Million CAD | -100.96% |
| 2006 | -3.34 Million CAD | 0.59% |
| 2005 | -3.36 Million CAD | 72.58% |
| 2004 | -12.25 Million CAD | -392.09% |
| 2003 | -2.49 Million CAD | 69.51% |
| 2002 | -8.16 Million CAD | 44.88% |
| 2001 | -14.82 Million CAD | 15.16% |
| 2000 | -17.46 Million CAD | -297.1% |
| 1999 | -4.39 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -26.1 Million CAD | 16.08% |
| 2024 Q2 | -21.17 Million CAD | 9.09% |
| 2023 Q1 | -15.3 Million CAD | -35.53% |
| 2023 FY | -31.11 Million CAD | -175.49% |
| 2023 Q4 | -31.11 Million CAD | 21.17% |
| 2023 Q3 | -39.46 Million CAD | -131.6% |
| 2023 Q2 | -17.04 Million CAD | -11.34% |
| 2022 Q4 | -11.29 Million CAD | 64.6% |
| 2022 Q1 | -38.89 Million CAD | 4.21% |
| 2022 Q2 | -33.16 Million CAD | 14.74% |
| 2022 FY | -11.29 Million CAD | 72.19% |
| 2022 Q3 | -31.9 Million CAD | 3.82% |
| 2021 Q1 | -49.73 Million CAD | -61.39% |
| 2021 Q2 | -50.05 Million CAD | -0.64% |
| 2021 Q3 | -47.37 Million CAD | 5.35% |
| 2021 Q4 | -40.6 Million CAD | 14.29% |
| 2021 FY | -40.6 Million CAD | -31.77% |
| 2020 FY | -30.81 Million CAD | -125.91% |
| 2020 Q4 | -30.81 Million CAD | -17.65% |
| 2020 Q2 | -29.58 Million CAD | 1.81% |
| 2020 Q3 | -26.19 Million CAD | 11.46% |
| 2020 Q1 | -30.13 Million CAD | -120.87% |
| 2019 Q1 | -13.43 Million CAD | 1.93% |
| 2019 Q3 | -11.69 Million CAD | -0.94% |
| 2019 Q4 | -13.64 Million CAD | -16.65% |
| 2019 FY | -13.64 Million CAD | 0.42% |
| 2019 Q2 | -11.58 Million CAD | 13.76% |
| 2018 Q1 | -7.74 Million CAD | 34.56% |
| 2018 FY | -13.69 Million CAD | -15.75% |
| 2018 Q4 | -13.69 Million CAD | 15.51% |
| 2018 Q3 | -16.21 Million CAD | 13.48% |
| 2018 Q2 | -18.74 Million CAD | -141.97% |
| 2017 Q3 | -14.03 Million CAD | 15.85% |
| 2017 FY | -11.83 Million CAD | 1.65% |
| 2017 Q1 | -10.1 Million CAD | 16.05% |
| 2017 Q4 | -11.83 Million CAD | 15.66% |
| 2017 Q2 | -16.67 Million CAD | -65.07% |
| 2016 Q1 | -20.23 Million CAD | 15.75% |
| 2016 Q2 | -18.32 Million CAD | 9.45% |
| 2016 Q3 | -15.61 Million CAD | 14.78% |
| 2016 Q4 | -12.03 Million CAD | 22.92% |
| 2016 FY | -12.03 Million CAD | 49.89% |
| 2015 Q4 | -24.01 Million CAD | 14.11% |
| 2015 Q1 | -28.57 Million CAD | -101.92% |
| 2015 FY | -24.01 Million CAD | -69.69% |
| 2015 Q3 | -27.96 Million CAD | 6.85% |
| 2015 Q2 | -30.01 Million CAD | -5.04% |
| 2014 Q4 | -14.15 Million CAD | 5.73% |
| 2014 Q2 | -16.88 Million CAD | 16.25% |
| 2014 Q1 | -20.15 Million CAD | 20.08% |
| 2014 FY | -14.15 Million CAD | 43.88% |
| 2014 Q3 | -15.01 Million CAD | 11.06% |
| 2013 Q2 | -36.15 Million CAD | 12.92% |
| 2013 Q1 | -41.51 Million CAD | -114.87% |
| 2013 Q4 | -25.22 Million CAD | 14.43% |
| 2013 Q3 | -29.47 Million CAD | 18.48% |
| 2013 FY | -25.22 Million CAD | -30.52% |
| 2012 Q1 | -44.62 Million CAD | -35.55% |
| 2012 Q4 | -19.32 Million CAD | 25.7% |
| 2012 FY | -19.32 Million CAD | 41.3% |
| 2012 Q2 | -33.8 Million CAD | 24.25% |
| 2012 Q3 | -26 Million CAD | 23.06% |
| 2011 Q1 | -49.91 Million CAD | -27.02% |
| 2011 FY | -32.91 Million CAD | 16.23% |
| 2011 Q4 | -32.91 Million CAD | 18.2% |
| 2011 Q3 | -40.24 Million CAD | 13.72% |
| 2011 Q2 | -46.64 Million CAD | 6.56% |
| 2010 Q2 | -23.2 Million CAD | 14.51% |
| 2010 Q3 | -16.09 Million CAD | 30.63% |
| 2010 Q4 | -39.29 Million CAD | -144.11% |
| 2010 FY | -39.29 Million CAD | -15.66% |
| 2010 Q1 | -27.14 Million CAD | 16.35% |
| 2009 Q2 | -11.98 Million CAD | -62.67% |
| 2009 FY | -33.97 Million CAD | -357.31% |
| 2009 Q4 | -32.44 Million CAD | -236.09% |
| 2009 Q3 | -9.65 Million CAD | 19.43% |
| 2009 Q1 | -7.36 Million CAD | 0.85% |
| 2008 Q3 | -12.68 Million CAD | -55.03% |
| 2008 FY | -7.42 Million CAD | -10.64% |
| 2008 Q1 | -7.32 Million CAD | -9.11% |
| 2008 Q2 | -8.17 Million CAD | -11.64% |
| 2008 Q4 | -7.42 Million CAD | 41.41% |
| 2007 Q2 | -6.92 Million CAD | 38.86% |
| 2007 Q3 | -3.32 Million CAD | 51.96% |
| 2007 FY | -6.71 Million CAD | -100.96% |
| 2007 Q1 | -11.32 Million CAD | -238.93% |
| 2007 Q4 | -6.71 Million CAD | -101.87% |
| 2006 Q2 | -7.07 Million CAD | -12.43% |
| 2006 FY | -3.34 Million CAD | 0.59% |
| 2006 Q4 | -3.34 Million CAD | 12.23% |
| 2006 Q3 | -3.8 Million CAD | 46.18% |
| 2006 Q1 | -6.29 Million CAD | -87.2% |
| 2005 Q1 | -8.31 Million CAD | 32.18% |
| 2005 Q3 | -4.52 Million CAD | 41.75% |
| 2005 Q2 | -7.76 Million CAD | 6.64% |
| 2005 Q4 | -3.36 Million CAD | 25.65% |
| 2005 FY | -3.36 Million CAD | 72.58% |
| 2004 Q1 | -2.79 Million CAD | -12.05% |
| 2004 Q2 | -2.9 Million CAD | -4.21% |
| 2004 Q3 | -2.35 Million CAD | 19.18% |
| 2004 Q4 | -12.25 Million CAD | -421.44% |
| 2004 FY | -12.25 Million CAD | -392.09% |
| 2003 Q1 | -6.73 Million CAD | 17.53% |
| 2003 Q2 | -13.33 Million CAD | -97.94% |
| 2003 Q3 | -3.66 Million CAD | 72.53% |
| 2003 Q4 | -2.49 Million CAD | 32.0% |
| 2003 FY | -2.49 Million CAD | 69.51% |
| 2002 Q1 | -11.86 Million CAD | 19.92% |
| 2002 Q3 | -7.58 Million CAD | 22.72% |
| 2002 Q4 | -8.16 Million CAD | -7.71% |
| 2002 FY | -8.16 Million CAD | 44.88% |
| 2002 Q2 | -9.81 Million CAD | 17.31% |
| 2001 FY | -14.82 Million CAD | 15.16% |
| 2001 Q1 | -16.95 Million CAD | 2.94% |
| 2001 Q4 | -14.82 Million CAD | 5.65% |
| 2001 Q2 | -16.48 Million CAD | 2.77% |
| 2001 Q3 | -15.7 Million CAD | 4.71% |
| 2000 Q4 | -17.46 Million CAD | 6.14% |
| 2000 Q2 | -17.01 Million CAD | 2.31% |
| 2000 FY | -17.46 Million CAD | -297.1% |
| 2000 Q1 | -17.41 Million CAD | 0.0% |
| 2000 Q3 | -18.61 Million CAD | -9.38% |
| 1999 FY | -4.39 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 484.544% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | -165.407% |
| Helix BioPharma Corp. | -1.08 Million CAD | -2777.983% |
| Microbix Biosystems Inc. | -4.96 Million CAD | -527.091% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | -83.2% |
| Satellos Bioscience Inc. | -22.06 Million CAD | -40.984% |
| Sernova Corp. | -8.58 Million CAD | -262.358% |